Inhibrx Biosciences, Inc. (INBX)
$
13.47
-0.28 (-2.08%)
Key metrics
Financial statements
Free cash flow per share
-10.9098
Market cap
199 Million
Price to sales ratio
995.2184
Debt to equity
0.0834
Current ratio
5.1190
Income quality
-0.0971
Average inventory
0
ROE
11.0119
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to developing biologic therapeutics for individuals facing life-threatening conditions. The company's therapeutic pipeline features INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5, currently undergoing phase 2 clinical trials aimed at treating unresectable or metastatic conventional chondrosarcoma. Additionally, INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4, is also in phase 2 clinical trials for various conditions, including metastatic solid tumors, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and operates out of La Jolla, California. The diluted EPS is $112.62 accounting for potential share dilution, while the weighted average number of shares outstanding is 14,475,904.00 highlighting the company's shareholder base. Furthermore, the gross profit ratio is -10.43 reflecting the efficiency of the company's production and sales operations. The company reported a net loss of $1,687,572,000.00 indicating challenges in its operations, and incurred an income tax expense of $2,000.00 which signifies its tax obligations. As a market entity, Inhibrx offers stock that is affordable at $13.75 making it a suitable option for budget-conscious investors. However, the stock has a low average trading volume of 113,952.00 indicating lower market activity. With a market capitalization of $194,990,427.00 the company is classified as a small-cap player within its niche. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape, and it belongs to the Healthcare sector, driving innovation and growth.
Is Inhibrx Biosciences, Inc. (INBX) a good investment?
Investing in Inhibrx Biosciences, Inc. (INBX) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as A, with a Bullish outlook. Always conduct your own research before investing.
What is Inhibrx Biosciences, Inc. (INBX)'s stock forecast?
Analysts predict Inhibrx Biosciences, Inc. stock to fluctuate between $10.80 (low) and $18.95 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Inhibrx Biosciences, Inc.'s market capitalization?
As of 2025-05-30, Inhibrx Biosciences, Inc.'s market cap is $194,990,427, based on 14,475,904 outstanding shares.
How does Inhibrx Biosciences, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Inhibrx Biosciences, Inc. has a Lower Market-Cap, indicating a difference in performance.
Does Inhibrx Biosciences, Inc. pay dividends?
Inhibrx Biosciences, Inc. pays dividends. The current dividend yield is 5.23%, with a payout of $0.85 per share.
How can I buy Inhibrx Biosciences, Inc. (INBX) stock?
To buy Inhibrx Biosciences, Inc. (INBX) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for INBX. Place an order (Market, Limit, etc.).
What is the best time to invest in Inhibrx Biosciences, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Inhibrx Biosciences, Inc. perform in the last earnings report?
Revenue: $200,000 | EPS: $114.01 | Growth: -2,326.76%.
Where can I find Inhibrx Biosciences, Inc.'s investor relations reports?
Visit https://inhibrx.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Inhibrx Biosciences, Inc.?
You can explore historical data from here
What is the all-time high and low for Inhibrx Biosciences, Inc. stock?
All-time high: $47.90 (2021-11-02) | All-time low: $7.67 (2022-06-16).
What are the key trends affecting Inhibrx Biosciences, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
prnewswire.com
17 days ago
SAN DIEGO , May 14, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the first quarter of 2025. Following the completion of the sale of INBRX-101 by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A.
prnewswire.com
2 months ago
SAN DIEGO , April 1, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with two programs in clinical-stage development, today announced the departure of Dr. Brendan Eckelman, co-founder and Chief Scientific Officer (CSO) and the appointments of Dr. Carlos Bais and David Matly to CSO and President, respectively. Dr. Eckelman leaves the Company to establish a newly-formed private biotechnology company, where he will be founder and Chief Executive Officer.
prnewswire.com
2 months ago
SAN DIEGO , March 17, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth quarter and fiscal year 2024. Following the completion of the sale of INBRX-101 by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A.
prnewswire.com
4 months ago
SAN DIEGO , Jan. 21, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced preliminary efficacy and safety data from the Phase 1 trial of ozekibart (INBRX-109) in combination with FOLFIRI for the treatment of advanced or metastatic, unresectable colorectal adenocarcinoma (CRC). These results were presented at the American Society of Clinical Oncology (ASCO) Gastrointestinal Annual Cancers Symposium.
prnewswire.com
5 months ago
SAN DIEGO , Jan. 13, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. ("Inhibrx" or the "Company") (Nasdaq: INBX), a biopharmaceutical company with two programs in ongoing clinical trials, today announced it entered into a loan and security agreement (the "LSA") with Oxford Finance LLC ("Oxford", together with certain of its affiliates party thereto, the "Lenders"), pursuant to which the Lenders provided a five-year term loan facility for up to $150 million (the "Credit Facility"). "This enables us strategic flexibility post data readouts expected later this year for our INBRX-109 and INBRX-106 programs," said Kelly Deck, Chief Financial Officer of Inhibrx.
prnewswire.com
7 months ago
SAN DIEGO , Nov. 14, 2024 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx Biosciences" or the "Company") today reported financial results for the third quarter of 2024. Following the completion of the sale of INBRX-101 by Inhibrx, Inc. (the "Former Parent") to Sanofi S.A.
seekingalpha.com
7 months ago
INBX's two main pipeline candidates, INBRX-109 and INBRX-106, are entering critical late-stage trials with data readouts expected in mid- to late-2025. INBRX-109 targets DR5 in solid tumors, showing promising early results but faces market skepticism due to past failures of similar molecules. Financially, INBX is well-funded with over $200 million in cash and last reported income of $2 billion, providing a potential cash runway through 2025.
prnewswire.com
7 months ago
SAN DIEGO , Nov. 4, 2024 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a biopharmaceutical company with two programs in ongoing clinical trials and a strong emerging pipeline, is pleased to announce a decisive legal victory in a trade secrets case brought by I-Mab Biopharma ("I-Mab") in the United States District Court for the District of Delaware. The jury found in favor of Inhibrx, rejecting all allegations of misappropriation before it, confirming the Company's adherence to high ethical standards and innovation in scientific research.
prnewswire.com
10 months ago
SAN DIEGO , Aug. 13, 2024 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx Biosciences" or the "Company"), a biopharmaceutical company with two programs in ongoing clinical trials and a strong emerging pipeline, today reported financial results for the second quarter of 2024 and provided an update on recent corporate highlights. Separation from the Former Parent In January 2024, Inhibrx, Inc. (the "Former Parent") announced its intent, as approved by its board of directors, to effect the spin-off of INBRX-101, an optimized, recombinant alpha-1 antitrypsin ("AAT"), augmentation therapy currently in a registrational trial for the treatment of patients with alpha-1 antitrypsin deficiency.
seekingalpha.com
a year ago
Inhibrx Biosciences, Inc.'s INBRX-109 is a tetravalent drug being developed for the treatment of patients with Ewing Sarcoma and other solid tumor types. It is expected that the Ewing Sarcoma Therapeutics market size could be worth as much as $424.42 million by 2032. INBRX-106 is a hexavalent drug being developed for the treatment of patients with multiple solid tumor types.
See all news
